Document is current

Any future updates will be listed below

Correction: Real‑world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post‑marketing surveillance in Japan

Crossref DOI link: https://doi.org/10.1007/s12185-025-03921-5

Published Online: 2025-02-26

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark